Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
China channel feed
This Chinese pharma filed for an IPO last September. Seven months and a $283M investment later, they are back at the HKEX
7 years ago
Financing
Chinese player joins a growing group of biotechs buying into Synaffix's ADC linker tech
7 years ago
Pharma
Vas Narasimhan has high hopes for Novartis' China drive as a blockbuster drug gets a nod
7 years ago
Eight months after filing for IPO, the maker of China's Ebola vaccine joins HKEX with $161M raise
7 years ago
R&D
Shanghai-based cancer drugmaker Abbisko lines up $42M B round as it makes a leap for the clinic
7 years ago
Financing
Oncology dominates a 'Cambrian explosion' in China's drug pipeline as McKinsey guru bets on a burst of innovation
7 years ago
Backed by OrbiMed, Lilly and now Advantech, China's InventisBio loads up $70M to propel cancer, metabolic pipeline
7 years ago
Financing
Abpro bags $60M in near-term R&D cash in tie-up with China's NJCTTQ, with eyes on bispecific T cell engagers
7 years ago
Pharma
In HKEX's first test in 2019, CStone seeks up to $304M in IPO fortune
7 years ago
Financing
Hillhouse Capital endorses China-based HaiHe Biopharma's cancer pipeline in $146M round
7 years ago
Financing
Zai Lab nabs speedy China regulatory review for PARP drug Zejula
7 years ago
Pharma
Mass cloning for neuro research? Chinese scientists report birth of five gene-edited monkeys
7 years ago
Discovery
Chinese government probe condemns Jiankui He as rogue scientist pursuing 'illegal' work on gene-edited babies
7 years ago
In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica
7 years ago
Pharma
Ramping up in-house drug development, API maker BrightGene bags $80M round led by Sequoia China
7 years ago
Financing
Prepping a cross-Pacific move, OrbiMed-backed Apollomics bags $100M Series B for I/O combos
7 years ago
Financing
With early-stage studies underway, Connect Biopharmaceuticals closes $55M round to advance immune modulators
7 years ago
Financing
Startups
China greenlights second homegrown PD-1 in 10 days as Innovent celebrates its first drug OK with Eli Lilly
7 years ago
Pharma
What other biotech news have you been missing? A big China IPO and more
7 years ago
Financing
FibroGen, AstraZeneca score China approval for anemia drug ahead of pivotal US data
7 years ago
Pharma
Junshi wins the race for first made-in-China PD-1 approval as execs reap $394M IPO harvest
7 years ago
Financing
Pharma
Broadening its oncology focus, Innovent adds three Incyte drugs to portfolio for $40M cash
7 years ago
R&D
Pharma
WuXi AppTec cruises toward a steady debut in Hong Kong stock exchange, ending flat on IPO price
7 years ago
Financing
Joining hunt for hep B cure, Brii Bio inks maiden deals featuring VBI, Vir, WuXi with a big appetite for more
7 years ago
Pharma
First page
Previous page
21
22
23
24
25
26
27
Next page
Last page